Log in
NASDAQ:CNSP

CNS Pharmaceuticals Stock Forecast, Price & News

$1.88
+0.06 (+3.30 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.81
Now: $1.88
$1.88
50-Day Range
$1.76
MA: $1.91
$2.24
52-Week Range
$1.26
Now: $1.88
$5.69
Volume6,500 shs
Average Volume119,206 shs
Market Capitalization$31.31 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
CNS Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, focuses on the development of anti-cancer drug candidates for the treatment of primary and metastatic brain, and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma. It has a development agreement with WPD Pharmaceuticals Inc. for the development of several preclinical drug candidates including WP1122, which will be tested on a range of viruses, including the coronavirus SARS-CoV-2. CNS Pharmaceuticals, Inc. was founded in 2017 and is based in Houston, Texas.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.20 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CNSP
CUSIPN/A
CIKN/A
Phone800-946-9185
Employees3

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.48 per share

Profitability

Net Income$-3,880,000.00

Miscellaneous

Market Cap$31.31 million
Next Earnings Date11/9/2020 (Estimated)
OptionableNot Optionable
$1.88
+0.06 (+3.30 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CNSP News and Ratings via Email

Sign-up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CNS Pharmaceuticals (NASDAQ:CNSP) Frequently Asked Questions

How has CNS Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

CNS Pharmaceuticals' stock was trading at $2.9050 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CNSP stock has decreased by 35.3% and is now trading at $1.88.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of CNS Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CNS Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for CNS Pharmaceuticals
.

When is CNS Pharmaceuticals' next earnings date?

CNS Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020.
View our earnings forecast for CNS Pharmaceuticals
.

How were CNS Pharmaceuticals' earnings last quarter?

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) posted its quarterly earnings results on Monday, August, 10th. The company reported ($0.15) EPS for the quarter.
View CNS Pharmaceuticals' earnings history
.

Are investors shorting CNS Pharmaceuticals?

CNS Pharmaceuticals saw a decline in short interest in September. As of September 15th, there was short interest totaling 90,500 shares, a decline of 25.6% from the August 31st total of 121,700 shares. Based on an average daily volume of 106,100 shares, the short-interest ratio is currently 0.9 days. Currently, 1.4% of the shares of the company are sold short.
View CNS Pharmaceuticals' Short Interest
.

Who are some of CNS Pharmaceuticals' key competitors?

What other stocks do shareholders of CNS Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CNS Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Advanced Micro Devices (AMD), Heat Biologics (HTBX), Roku (ROKU), Aldeyra Therapeutics (ALDX), salesforce.com (CRM), Gilead Sciences (GILD), Inseego (INSG), Nokia (NOK) and Square (SQ).

Who are CNS Pharmaceuticals' key executives?

CNS Pharmaceuticals' management team includes the following people:
  • Mr. John Michael Climaco Esq., J.D., Chairman, CEO & Pres (Age 51, Pay $423.07k)
  • Mr. Christopher S. Downs, Chief Financial Officer (Age 41, Pay $68.41k)
  • Dr. Sandra L. Silberman, Chief Medical Officer (Age 64, Pay $43.42k)
  • Dr. Waldemar Priebe Ph.D., Founder & Chairman of the Scientific Advisory Board
  • Dr. Donald H. Picker, Chief Science Officer (Age 74)

When did CNS Pharmaceuticals IPO?

(CNSP) raised $9 million in an initial public offering (IPO) on Friday, November 8th 2019. The company issued 2,100,000 shares at a price of $4.00-$5.00 per share. Benchmark served as the underwriter for the IPO.

What is CNS Pharmaceuticals' stock symbol?

CNS Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNSP."

How do I buy shares of CNS Pharmaceuticals?

Shares of CNSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CNS Pharmaceuticals' stock price today?

One share of CNSP stock can currently be purchased for approximately $1.88.

How big of a company is CNS Pharmaceuticals?

CNS Pharmaceuticals has a market capitalization of $31.31 million. The company earns $-3,880,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis. CNS Pharmaceuticals employs 3 workers across the globe.

What is CNS Pharmaceuticals' official website?

The official website for CNS Pharmaceuticals is www.cnspharma.com.

How can I contact CNS Pharmaceuticals?

CNS Pharmaceuticals' mailing address is 2100 WEST LOOP SOUTH SUITE 900, HOUSTON TX, 77027. The company can be reached via phone at 800-946-9185 or via email at [email protected]

This page was last updated on 10/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.